Tranexamic acid dosage regimens on blood loss in Hemi-Mandibulectomy

Phase 4

• Conditions: Oral Health

• Registration Number: PACTR202110492542153
• Lead Sponsor: Dr. Okoro Ndidi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-10-07
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

1. Willing and consenting patients aged 18-64years,
2. Healthy and physical status I and II according to the American Society of Anaesthesiologists (ASA) physical status classification

Exclusion Criteria

1.Patients who refused to participate
2.Patients with known allergy to tranexamic acid
3.Patients with history or risk of thromboembolism (including patients on oral contraceptive pills, and anticoagulants)’
4. Patients with uncontrolled hypertension, renal or hepatic dysfunction and coagulopathy,
5.Patients with likelihood of difficult intubation (Mallampati III and IV) were excluded from the study
6.Patients with haematological diseases or any form of bleeding diathesis following the review of the clotting profile including platelet count less than 150000/m3
7. Patients with a history of convulsion

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Amount of Blood loss in millilitres

Secondary Outcome Measures

Name	Time	Method
nits of Blood transfused in pints;Duration of operation in minutes